Streetbeat News

Analyst Ratings

SBUX

TD Cowen analyst Agnes Lim reiterates an Outperform rating on Starbucks (NASDAQ:SBUX) and maintains a $117 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 11:04 am

EPAM

Morgan Stanley analyst James Faucette downgraded EPAM Systems (NYSE:EPAM) from Overweight to Equal-Weight and lowered the price target from $350 to $220.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 11:03 am

LEGN

HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintains an $82 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:47 am

NB

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on NioCorp Developments (NASDAQ:NB) but lowers the price target from $14 to $13.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:42 am

OCUL

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:40 am

CRNX

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:39 am

FDMT

HC Wainwright & Co. analyst Matthew Caufield reiterates a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintains a $36 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:18 am

SCPH

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH) and maintained an $18 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:17 am

AADI

HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Aadi Bioscience (NASDAQ:AADI) and maintained a $45 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:16 am

KNTE

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Kinnate Biopharma (NASDAQ:KNTE) and maintained a $24 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:15 am